ANRO
Alto Neuroscience, Inc.Company Information
- Company Name
- Alto Neuroscience, Inc.
- CIK
- CIK0001999480
- Category
- <br>Emerging growth company
- Ticker: Exchange
- ANRO: NYSE
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- ANRO
SEC filing data through
Insider Sentiment
- Last purchase
- 2024-07-10
- Last sale
- —
- Shares purchased (TTM)
- 630,769
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 29,139,462
- Shares outstanding
- 42,813,000
- Ownership
- 68.06%
Earnings Market Reaction
- Filing date
- 2026-08-12
- Price on filing date
- —
- 1-month reaction
- 21.83%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 244 | 264 | 176 | 138 | 148 | 161 | 168 | 182 | 193 | 206 | ||||||
| Other Receivables Net Current | - | - | - | - | - | - | - | 0 | 0 | 0 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 5 | 1 | 2 | 2 | 3 | 1 | 2 | 2 | 2 | ||||||
| Assets Current | 247 | 269 | 178 | 139 | 150 | 164 | 169 | 184 | 195 | 208 | ||||||
| Restricted Cash Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | - | ||||||
| Property Plant And Equipment Net | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 1 | 2 | ||||||
| Operating Lease Right Of Use Asset | 4 | 4 | 4 | 4 | 5 | 5 | 5 | 5 | - | - | ||||||
| Other Assets | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Assets | 254 | 276 | 185 | 147 | 158 | 172 | 178 | 192 | 197 | 210 | ||||||
Liabilities Current | ||||||||||||||||
| Accounts Payable Current | 4 | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 2 | 2 | ||||||
| Accrued Liabilities Current | 9 | 8 | 9 | 7 | 6 | 6 | 8 | 8 | 6 | 4 | ||||||
| Long Term Debt Current | 4 | 2 | 1 | - | - | - | 0 | 4 | 2 | 1 | ||||||
| Liabilities Current | 17 | 13 | 11 | 9 | 8 | 7 | 10 | 14 | 10 | 8 | ||||||
| Long Term Debt Noncurrent | 12 | 14 | 16 | 20 | 20 | 20 | 10 | 7 | 8 | 9 | ||||||
| Convertible Debt | 2 | 2 | 2 | 2 | 2 | 1 | 1 | 1 | - | - | ||||||
| Warrants And Rights Outstanding | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Operating Lease Liability Noncurrent | 3 | 4 | 4 | 4 | 4 | 4 | 5 | 5 | - | - | ||||||
| Liabilities | 35 | 33 | 34 | 35 | 34 | 33 | 26 | 27 | 18 | 17 | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | 0 | - | - | - | 0 | 0 | 0 | 0 | ||||||
Stockholders Equity Note | ||||||||||||||||
| Common Stock Value Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 475 | 471 | 353 | 297 | 295 | 293 | 290 | 288 | 286 | 284 | ||||||
| Retained Earnings Accumulated Deficit | -256 | -228 | -202 | -185 | -171 | -154 | -138 | -123 | -106 | -90 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | 0 | 0 | 0 | 0 | 0 | 0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 219 | 243 | 151 | 112 | 123 | 139 | 151 | 165 | 180 | 193 | ||||||
| Liabilities And Stockholders Equity | 254 | 276 | 185 | 147 | 158 | 172 | 178 | 192 | 197 | 210 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | - | - | ||||||
| Common Stock Shares Issued | 35 | 35 | 32 | 27 | 27 | 27 | 27 | 27 | - | - | ||||||
| Shares Outstanding | 35 | 35 | 32 | 27 | 27 | 27 | 27 | 27 | - | - | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialAlto Neuroscience, Inc. (ANRO) — SEC Financial Statements & Analysis
Alto Neuroscience, Inc. (ANRO) is a pharmaceutical preparations company, incorporated in DE. Alto Neuroscience, Inc. trades on NYSE as: ANRO. Alto Neuroscience, Inc. (ANRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12. Based on that filing, Alto Neuroscience, Inc. carries a market cap of $1.13B, a P/E ratio of -13.41x, a P/B ratio of 5.15x, an enterprise value of $901.79M, and an EV/EBITDA multiple of -10.31x. On profitability, it posts a Return on Equity (ROE) of -49.17% and a Return on Assets (ROA) of -40.90%. Per share, it reports EPS of $-1.97, diluted EPS of $-1.97, free cash flow per share of $-1.61, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 29.88% year-over-year and EPS growth of -17.87% year-over-year. On the balance sheet, it maintains a current ratio of 14.85x, a quick ratio of 14.64x, working capital of $230.67M, a debt-to-equity ratio of 0.16x, a debt ratio of 0.14, an interest coverage ratio of -39.04x, free cash flow of $-68.84M (TTM), and net debt of $-228.05M. Figures sourced from SEC EDGAR.
- Market Cap
- $1.13B
- P/E TTM
- -13.41x
- EPS TTM
- $-1.97
- P/B TTM
- 5.15x
- ROE TTM
- -49.17%
- ROA TTM
- -40.90%
- Debt To Equity
- 0.16x
- Free Cash Flow TTM
- $-68.84M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Alto Neuroscience, Inc. in?
Alto Neuroscience, Inc. (ANRO) operates in the Pharmaceutical Preparations industry.
What exchange does ANRO trade on?
Alto Neuroscience, Inc. (ANRO) trades on the NYSE.
Where is Alto Neuroscience, Inc. incorporated?
Alto Neuroscience, Inc. is incorporated in DE.
When was Alto Neuroscience, Inc. (ANRO)'s most recent SEC filing?
Alto Neuroscience, Inc. (ANRO)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-12.
What is ANRO's market cap?
Alto Neuroscience, Inc. (ANRO) has a market capitalization of $1.13B as of 2026-06-30.
What is ANRO's EPS (earnings per share)?
Alto Neuroscience, Inc. (ANRO)'s trailing twelve month EPS is $-1.97 as of 2026-06-30.
What is ANRO's ROE (return on equity)?
Alto Neuroscience, Inc. (ANRO)'s trailing twelve month Return on Equity (ROE) is -49.17% as of 2026-06-30.
What is ANRO's ROA (return on assets)?
Alto Neuroscience, Inc. (ANRO)'s trailing twelve month Return on Assets (ROA) is -40.90% as of 2026-06-30.
What is ANRO's EV/EBITDA?
Alto Neuroscience, Inc. (ANRO)'s trailing twelve month EV/EBITDA is -10.31x as of 2026-06-30.